High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial

Abstract

Short-term use of atorvastatin was associated with modest but statistically significant reductions in the proportion of activated T lymphocytes.